SCHEDULE 13G: Richard K. Crumly and Affiliates Disclose 11.2% Stake in bioAffinity Technologies

Richard K. Crumly, along with ADAMAS LLC and BMUS PARTNERS LLC, has filed a Schedule 13G disclosing a collective beneficial ownership of 11.2% of bioAffinity Technologies, Inc.'s common stock.

Summary

• Richard K. Crumly, ADAMAS LLC, and BMUS PARTNERS LLC (collectively, the "Reporting Persons") have jointly filed a Schedule 13G with the SEC.
• The Reporting Persons collectively beneficially own 3,213,777 shares of bioAffinity Technologies, Inc. common stock.
• This ownership represents 11.2% of the outstanding common stock of bioAffinity Technologies, Inc.
• The percentage is calculated based on 27,249,462 shares of common stock outstanding as of May 8, 2025, as reported by the Issuer.
• Richard K. Crumly's beneficial ownership includes 1,406,250 warrants, which represent a contingent right to acquire an equal number of common shares upon immediate exercise.
• Mr. Crumly is identified as a control person for both ADAMAS LLC and BMUS PARTNERS LLC, and their respective shareholdings are included in his aggregate beneficial ownership.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership, which is inherently neutral in tone regarding company performance or outlook.

Positives

• The filing provides increased transparency regarding significant beneficial ownership in bioAffinity Technologies, Inc.
• The disclosure of a substantial stake by Richard K. Crumly and his affiliated entities may signal confidence from a notable investor.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant ownership stake, which can influence market perception and potentially signal investor confidence.

Key Dates

Keywords

bioAffinity Technologies, Common Stock, Schedule 13G, Beneficial Ownership, Richard K. Crumly, ADAMAS LLC, BMUS PARTNERS LLC, SEC Filing, Ownership Stake, Warrants